Transaction DateRecipientSharesTypePriceValue
30th September 2020Mark A Goldsmith42,548Exercise of derivative$4.73$201,252.04
30th September 2020Mark A Goldsmith1,312Open or private sale$34.12$44,762.29
30th September 2020Mark A Goldsmith42,578Open or private sale$34.40$1,464,853.51
30th September 2020Mark A Goldsmith30Exercise of derivative$1.12$33.60
29th September 2020Mark A Goldsmith21,088Open or private sale$34.08$718,651.63
29th September 2020Mark A Goldsmith20,076Exercise of derivative$4.73$94,959.48
29th September 2020Mark A Goldsmith30,523Open or private sale$34.14$1,041,917.87
29th September 2020Mark A Goldsmith10,447Exercise of derivative$4.09$42,728.23
28th September 2020Mark A Goldsmith10,132Exercise of derivative$4.09$41,439.88
28th September 2020Mark A Goldsmith10,132Open or private sale$34.11$345,567.06
Constellation Pharmaceuticals
Constellation Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.

Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel therapeutics in the field of epigenetics. Its product candidates include CPI-0610, CPI-1205, and CPI-0209.

Ticker: CNST
Sector: Health Technology
Industry: Pharmaceuticals: Major
SEC Central Index Key (CIK): 1434418
Employees: 106
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $179 M (0%)
Marketable Securities, Current: $341 M (588%)
Assets, Current: $523 M (35%)
Property, Plant and Equipment, Net: $1 M (48%)
Assets: $535 M (33%)
Long-term Debt, Current Maturities: $2 M (0%)
Accounts Payable, Current: $6 M (-22%)
Liabilities, Current: $27 M (19%)
Long-term Debt, Excluding Current Maturities: $28 M (0%)
Other Liabilities, Noncurrent: $716 Th (83%)
Liabilities: $63 M (2%)
Common Stock, Value, Issued: $5 Th (25%)
Common Stock, Shares, Issued: $48 M (13%)
Additional Paid in Capital, Common Stock: $846 M (28%)
Retained Earnings (Accumulated Deficit): $375 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $255 Th (4150%)
Stockholders' Equity (Parent): $472 M (0%)
Liabilities and Equity: $535 M (33%)
Research and Development: $23 M (-47%)
General and Administrative Expenses: $7 M (-45%)
Operating Income/Loss: $30 M (-46%)
Other Income, net: $142 Th (-65%)
Provision for income taxes: $24 Th (-38%)